These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29572186)

  • 1. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients.
    Dalal V; Kumar R; Kumar S; Sharma A; Kumar L; Sharma JB; Roy KK; Singh N; Vanamail P
    Clin Chim Acta; 2018 Jul; 482():27-32. PubMed ID: 29572186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer.
    Zeimet AG; Widschwendter M; Knabbe C; Fuchs D; Herold M; Müller-Holzner E; Daxenbichler G; Offner FA; Dapunt O; Marth C
    J Clin Oncol; 1998 May; 16(5):1861-8. PubMed ID: 9586902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of VEGF, IL-8 and beta-FGF concentrations in the serum and ascites of patients with ovarian cancer].
    Sadłecki P; Walentowicz-Sadłecka M; Szymański W; Grabiec M
    Ginekol Pol; 2011 Jul; 82(7):498-502. PubMed ID: 21913426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients.
    Huo J; Hu J; Liu G; Cui Y; Ju Y
    Arch Gynecol Obstet; 2017 Feb; 295(2):459-465. PubMed ID: 27975129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring.
    Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
    J Ovarian Res; 2015 Aug; 8():58. PubMed ID: 26282935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.
    Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
    Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients.
    Lane D; Matte I; Rancourt C; Piché A
    BMC Cancer; 2011 May; 11():210. PubMed ID: 21619709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).
    Rohr I; Braicu EI; En-Nia A; Heinrich M; Richter R; Chekerov R; Dechend R; Heidecke H; Dragun D; Schäfer R; Gorny X; Lindquist JA; Brandt S; Sehouli J; Mertens PR
    Cytokine; 2016 Sep; 85():157-64. PubMed ID: 27371774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of TBC1D16 Is Associated with Favorable Prognosis of Epithelial Ovarian Cancer.
    Yang Z; Shen H; He W; Ouyang L; Guo Y; Qian F; Xu B; Xie D; Yang G
    Tohoku J Exp Med; 2018 Jul; 245(3):141-148. PubMed ID: 29962380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
    Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
    Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
    Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
    Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer.
    Cândido EB; Silva LM; Carvalho AT; Lamaita RM; Filho RM; Cota BD; da Silva-Filho AL
    Reprod Sci; 2013 Jul; 20(7):828-37. PubMed ID: 23239818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of osteopontin in the management of epithelial ovarian cancer.
    Cerne K; Hadzialjevic B; Skof E; Verdenik I; Kobal B
    Radiol Oncol; 2019 Jan; 53(1):105-115. PubMed ID: 30712025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer.
    Moradi MM; Carson LF; Weinberg B; Haney AF; Twiggs LB; Ramakrishnan S
    Cancer; 1993 Oct; 72(8):2433-40. PubMed ID: 8402460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels.
    Yamamoto S; Konishi I; Mandai M; Kuroda H; Komatsu T; Nanbu K; Sakahara H; Mori T
    Br J Cancer; 1997; 76(9):1221-7. PubMed ID: 9365173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer.
    Komatsu H; Oishi T; Itamochi H; Shimada M; Sato S; Chikumi J; Sato S; Nonaka M; Sawada M; Wakahara M; Umekita Y; Harada T
    Int J Gynecol Cancer; 2017 Sep; 27(7):1325-1332. PubMed ID: 28557832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ascites N-glycome of epithelial ovarian cancer patients.
    Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
    J Proteomics; 2017 Mar; 157():33-39. PubMed ID: 28188862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular Endothelial Growth Factor (VEGF) Polymorphisms and Serum VEGF Levels in Women With Epithelial Ovarian Cancer, Benign Tumors, and Healthy Ovaries.
    González-Palomares B; Coronado Martín PJ; Maestro de Las Casas ML; Veganzones de Castro S; Rafael Fernández S; Vidaurreta Lázaro M; De la Orden García V; Vidart Aragon JA
    Int J Gynecol Cancer; 2017 Jul; 27(6):1088-1095. PubMed ID: 28574932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.